NasdaqGS - Nasdaq Real Time Price USD

Alnylam Pharmaceuticals, Inc. (ALNY)

150.47 -0.90 (-0.59%)
At close: May 10 at 4:00 PM EDT
151.04 +0.57 (+0.38%)
After hours: May 10 at 7:05 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
2,003,335.00
1,828,292.00
1,037,418.00
844,287.00
492,853.00
Cost of Revenue
321,513.00
310,406.00
168,817.00
140,144.00
78,052.00
Gross Profit
1,681,822.00
1,517,886.00
868,601.00
704,143.00
414,801.00
Operating Expense
1,857,625.00
1,800,061.00
1,653,673.00
1,412,795.00
1,243,239.00
Operating Income
-175,803.00
-282,175.00
-785,072.00
-708,652.00
-828,438.00
Net Non Operating Interest Income Expense
-20,968.00
-25,660.00
-131,160.00
-141,442.00
-72,687.00
Other Income Expense
-127,971.00
-125,682.00
-210,761.00
-2,050.00
45,525.00
Pretax Income
-324,742.00
-433,517.00
-1,126,993.00
-852,144.00
-855,600.00
Tax Provision
7,334.00
6,725.00
4,163.00
680.00
2,681.00
Net Income Common Stockholders
-332,076.00
-440,242.00
-1,131,156.00
-852,824.00
-858,281.00
Diluted NI Available to Com Stockholders
-332,076.00
-440,242.00
-1,131,156.00
-852,824.00
-858,281.00
Basic EPS
-2.64
-3.52
-9.30
-7.20
-7.46
Diluted EPS
-2.64
-3.52
-9.30
-7.20
-7.46
Basic Average Shares
125,412.75
124,906.00
121,689.00
118,451.00
114,986.00
Diluted Average Shares
125,412.75
124,906.00
121,689.00
118,451.00
114,986.00
Total Operating Income as Reported
-175,803.00
-282,175.00
-785,072.00
-708,652.00
-828,438.00
Rent Expense Supplemental
147,454.00
145,687.00
131,967.00
97,259.00
--
Total Expenses
2,179,138.00
2,110,467.00
1,822,490.00
1,552,939.00
1,321,291.00
Net Income from Continuing & Discontinued Operation
-332,076.00
-440,242.00
-1,131,156.00
-852,824.00
-858,281.00
Normalized Income
-267,449.40
-354,968.61
-969,555.97
-865,425.26
-885,186.61
Interest Income
106,551.00
95,561.00
24,808.00
1,579.00
11,809.00
Interest Expense
127,519.00
121,221.00
155,968.00
143,021.00
84,496.00
Net Interest Income
-20,968.00
-25,660.00
-131,160.00
-141,442.00
-72,687.00
EBIT
-197,223.00
-312,296.00
-971,025.00
-709,123.00
-771,104.00
EBITDA
-100,785.00
-215,265.00
-885,475.00
-619,429.00
-696,669.00
Reconciled Cost of Revenue
321,513.00
310,406.00
168,817.00
140,144.00
78,052.00
Reconciled Depreciation
96,438.00
97,031.00
85,550.00
89,694.00
74,435.00
Net Income from Continuing Operation Net Minority Interest
-332,076.00
-440,242.00
-1,131,156.00
-852,824.00
-858,281.00
Total Unusual Items Excluding Goodwill
-107,711.00
-107,941.00
-204,557.00
17,262.00
36,857.00
Total Unusual Items
-107,711.00
-107,941.00
-204,557.00
17,262.00
36,857.00
Normalized EBITDA
6,926.00
-107,324.00
-680,918.00
-636,691.00
-733,526.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
-43,084.40
-22,667.61
-42,956.97
4,660.74
9,951.39
12/31/2020 - 6/1/2004

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

IONS Ionis Pharmaceuticals, Inc.
39.08
-0.99%
 
ARWR Arrowhead Pharmaceuticals, Inc.
22.08
-10.68%
 
BMRN BioMarin Pharmaceutical Inc.
81.03
-0.84%
 
ARGX argenx SE
374.63
-2.07%
 
BGNE BeiGene, Ltd.
161.13
-4.45%
 
INCY Incyte Corporation
53.06
-0.82%
 
BBIO BridgeBio Pharma, Inc.
29.10
+1.29%
 
LEGN Legend Biotech Corporation
43.24
-5.01%
 
APLS Apellis Pharmaceuticals, Inc.
41.99
-1.25%
 
KRYS Krystal Biotech, Inc.
154.76
-2.50%